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ABSTRACT
Infant formula should provide the appropriate nutrients and adequate energy to facilitate healthy infant growth and development. If conclusive
data on quantitative nutrient requirements are not available, the composition of human milk (HM) can provide some initial guidance on the infant
formula composition. This paper provides a narrative review of the current knowledge, unresolved questions, and future research needs in the
area of HM fatty acid (FA) composition, with a particular focus on exploring appropriate intake levels of the essential FA linoleic acid (LA) in infant
formula. The paper highlights a clear gap in clinical evidence as to the impact of LA levels in HM or formula on infant outcomes, such as growth,
development, and long-term health. The available preclinical information suggests potential disadvantages of high LA intake in the early postnatal
period. We recommend performing well-designed clinical intervention trials to create clarity on optimal levels of LA to achieve positive impacts on
both short-term growth and development and long-term functional health outcomes. Adv Nutr 2021;00:1–14.
Statement of Significance: The present work summarizes and discusses for the first time the (gaps in) available evidence on the effects of
linoleic acid in an infant diet on infant health outcomes in relation to the recently adapted changes in regulations for the addition of linoleic
acid to infant formula.
Keywords: linoleic acid, LCPUFAs, human milk composition, infant development, infant formula, nutritional programming
Introduction
Exclusive breastfeeding is recommended for infants up to
6 months of age, with continued breastfeeding thereafter
in conjunction with appropriate complementary feeding
until 2 years of age or beyond (1). Lipids make up a
substantial proportion of human milk (HM) macronutrients
and provide around 50% of the total energy needs for the
infant. The HM fatty acid (FA) profile is diverse, with over
200 FA species in varying isoforms and concentrations (2).
The most abundant FAs in HM (>50% of the FAs) are
saturated fatty acids, followed by MUFAs and PUFAs. PUFAs
of various carbon chain lengths can be further classified as n–
3 or n–6, depending on the location of the last double bond
from the carboxyl end of the FA chain. HM n–3 and n–6
PUFAs include the essential fatty acids (EFAs) linoleic acid
(LA; 18:2 n–6) and α-linolenic acid (ALA; 18:3 n–3), ranging
between 5%–30% and 0.3%–2% of total FA, respectively, as
reviewed previously (2, 3). However, these levels may vary
depending on various maternal nutritional, lifestyle, and
genetic factors.
LA and ALA are the predominant dietary PUFAs and
the main substrates to produce the long-chain PUFAs
(LCPUFAs), particularly arachidonic acid (ARA; 20:4 n–
6) and DHA (22:6 n–3). Preclinical evidence suggests that
preformed ARA and DHA may meet needs for EFAs,
indicating that LA and ALA are not essential if sufficient ARA
C© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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and DHA are provided (4). ARA and DHA are also present
in HM, although at much lower levels than their precursors,
with reported ranges between 0.1%–1.1% and up to 1.4% of
the total FAs for ARA and DHA, respectively (2, 5), with the
levels of DHA being largely dependent on the maternal diet
(6–8). Though the relationship between the maternal dietary
intake and HM concentration has not been determined for
all PUFAs, the available evidence suggests that their wide
range in HM reflects variations in maternal dietary intakes
and maternal genotypes (9).
HM substitutes (i.e., infant formula) should provide a safe
and nutritionally adequate alternative if full breastfeeding is
not possible. Absent conclusive evidence on infant nutrient
needs, knowledge of the physiology and composition of
HM may provide some first guidance on designing the
composition of infant formulas, along with scientific data
from experimental and human studies on nutritional needs,
safety, and biological effects.
While our knowledge of HM FA compositions and
infant FA metabolisms has increased over the last several
decades, new scientific insights and improved analytical
techniques have highlighted the substantial variability in the
concentrations of FAs in HM and the complex relationships
among them. This suggests that requirements may vary
among individual infants and complicates the formulation
of infant nutritional guidelines. The variable fat content and
FA compositions of weaning foods further affect overall FA
intakes and our ability to assess the kinds and amounts of
FAs infants need (10–12). A challenge for the formulation
of guidelines on FA compositions in infant nutrition is the
absence of reliable data on precise nutritional requirements
for healthy infant growth and development and later-
life health outcomes. The current narrative review paper
summarizes an expert discussion on the topic initiated and
organized by Danone Nutricia Research. It aims at providing
an overview on the available evidence that may guide the
definition of appropriate infant formula FA compositions,
with an emphasis on LA.
The current paper is the outcome of a series of discussion sessions initiated and facilitated by
Danone Nutricia Research (DNR), in which all coauthors actively participated. SEC, JTB, CA, PCC,
SF, PL, BVK, and BM received an expense allowance from (DNR) to compensate for their effort.
Author disclosures: SEC, JTB, CA, PCC, SF, PL, BVK, and BM received an expense allowance from
Danone Nutricia Research (DNR) to compensate for their effort. LS, MA-B, and BJMvdH are
employed by DNR. EMvdB was employed by DNR at the time of the topic discussions. BVK is the
Else Kröner Senior Professor of Paediatrics, a position cofunded by the Else Kröner–Fresenius
Foundation, Bad Homburg, Germany, and Ludwig Maximilian University of Munich Hospitals.
Danone Nutricia Research contributed to the discussion, the interpretation of the outcomes,
and the design of the paper.
Perspective articles allow authors to take a position on a topic of current major importance or
controversy in the field of nutrition. As such, these articles could include statements based on
author opinions or point of view. Opinions expressed in Perspective articles are those of the
author and are not attributable to the funder(s) or the sponsor(s) or the publisher, Editor, or
Editorial Board of Advances in Nutrition. Individuals with different positions on the topic of a
Perspective are invited to submit their comments in the form of a Perspectives article or in a
Letter to the Editor.
Address correspondence to SEC (e-mail: scarlson@kumc.edu).
Abbreviations used: ALA, α-linolenic acid; ARA, arachidonic acid; DPA, docosapentaenoic acid;
EC, European Commission; EFA, essential fatty acid; EFSA, European Food Safety Authority; FA,
fatty acid; FADS, fatty acid desaturase; HM, human milk; LA, linoleic acid; LCPUFA, long-chain
PUFA; RCT, randomized controlled trial; WAT, white adipose tissue.
Infant FA Requirements
Nutrient levels in formula should ideally be adequate for
all infants, while recognizing that optimal levels may not
be the same for all, depending on genetic, other biological,
and environmental factors. However, a challenge for the
formulation of guidelines on PUFA intakes for infants is the
limited existing data on the precise nutritional requirements
for healthy growth and development and support of optimal
long-term health outcomes. There is evidence that specific
subgroups of infants have different FA requirements to the
general infant population. For example, infants born preterm
miss out on part of the in utero accumulation of DHA and
ARA in their brain and other tissues that would normally
accelerate during the third trimester, and have lower brain
ARA and DHA at birth than infants born at term (13).
Half of the brain DHA accretion at term occurs in the last
5 weeks of gestation (13–16). Preterm infants are at risk for
neurodevelopmental problems and may benefit from ARA
and DHA supplementation in the postnatal period (17–
20), although there is limited evidence of beneficial effects
on neurodevelopmental outcomes in the longer term (21).
Compared to preterm and (very) low birth-weight infants,
our understanding of the FA needs of infants born with a
high birth weight or to women with obesity or diabetes is
even more limited. Some evidence suggests that maternal and
cord blood DHA concentrations are reduced in pregnancies
complicated by maternal gestational diabetes (22), raising
the possibility of an increased n–3 LCPUFA requirement
postnatally.
It is likely that even among healthy, term infants there
is a considerable variation in PUFA requirements based
on phenotype, genotype, and (maternal) environmental
factors. For instance, the FA metabolism is likely to be
sexually dimorphic, given that sex differences in response
to PUFA interventions have been reported in numerous
infant studies (23). In addition, genetic variation in the
FA desaturase (FADS) gene cluster determines the infant’s
capacity for endogenous synthesis of ARA and DHA from
their precursors, and so may result in different nutritional
needs and related disease risks (24). In support of this,
children with the poor conversion phenotype (haplotype A
compared with D) have a 2-fold higher risk of developing
asthma if their DHA supply after birth is low (24, 25).
Likewise, maternal diet, health, and lifestyle, as well as
other environmental factors such as smoking, modulate the
fetal FA supply and PUFA status at birth (26, 27), which
suggests specific nutritional needs may arise for n–6 and n–3
LCPUFAs in the postnatal period.
Acknowledging individual variability in the FA status at
birth, the requirements for specific PUFAs in formula may
best be described as a range rather than a single value. Gen-
erally, it is assumed that the estimated average requirement
plus/minus 2 SDs of the variation in infant requirements
will cover the needs of almost all healthy individuals in
a population. Crossing either side of the lower or upper
margin could increase the risk of negative consequences
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for the infant’s metabolism, physiological functions, and
short- and long-term health outcomes. Although in theory
this seems plausible, the current evidence is too limited
to provide a strong rationale for clear cutoff values for
specific FAs. As an example, adverse health effects were
observed in clinical studies conducted in the 1940s and
1950s using experimental infant feeding concepts with very
low LA levels (see also below). Although they provided
valuable information on minimal requirements of LA (28),
these studies were conducted using formulas with very low
fat contents and devoid of preformed LCPUFAs, and are
therefore not comparable to the infant formulas currently on
the market.
In contrast, infant formula marketed in the Netherlands
in the early 1970s provided as much as 58% of FAs as LA,
resulting in very high LA contents in infant body fat (29), and
an early study in the United States of infants fed formula with
45% of FAs as LA found 2- to 3-fold higher LA contents of red
blood cell phospholipid classes compared to breastfed infants
(30). No obvious adverse health effects were reported in these
studies (30, 31). Clinical studies to investigate dietary levels of
all FAs are impractical, if not impossible, and thus guidance
is needed from careful consideration of scientific evidence,
including an in-depth understanding of HM composition
and preclinical studies.
HM Composition May Provide Guidance on
Adequate Infant FA Intakes
The nutritional and functional properties of infant formula
should ensure healthy growth and development, serving
a similar function and providing similar benefits as HM
as much as possible. HM composition is believed to be
selected by evolution to provide the nutrients and energy
to support adequate growth and development of human
infants (32), and thus provides some guidance as to infant
FA intakes that are likely adequate, even though the HM
lipid composition varies markedly. It is also important to
consider that an identical intake level of a substrate in infant
formula as observed in HM does not by itself ensure safety
and suitability. For instance, the bioavailability of a given
substance may differ between the formula and HM matrix
and/or there may be subtle differences in the conformation
of a substrate added to infant formula in comparison to
the naturally occurring substance in HM (33). To date,
recommendations for the lipid composition of infant formula
have been guided partly by data on the lipid composition of
HM (34), while acknowledging that exact mimicking of the
HM composition may be neither possible nor favorable per
se. For example, some components of HM might be present as
a consequence of the mechanisms of HM synthesis, maternal
diet, or other environmental factors, such as exposure to
lipid-soluble pollutants without any nutritional or other
benefit for the infant (35). Other components, such as
hormones and other biologically active components present
in HM, cannot be added to infant formula at this time
because of sourcing, technological, regulatory, or food safety
reasons.
More than 200 different FA species have been described in
HM. For most, their relevance to the health and development
of the infant is unknown. For some FAs, it is uncertain
whether they are present in HM in all women. The variation
in FA profiles in milk of healthy, omnivorous women could be
used as a base to define appropriate ranges; however, several
aspects need to be considered.
First, HM fat content and FA composition change con-
siderably over the course of lactation (36, 37). It has been
postulated that some of these changes may match changing
nutritional requirements of the growing/developing infant.
For example, the observed increase in fat content with
a concomitant decrease of protein-to-fat and protein-to-
energy ratios during the transition from colostrum to mature
milk is likely to reflect the decreasing weight gain velocity
with an increasing postnatal age (32). The determinants and
biological relevance of changes in the FA composition of
HM during the transition to mature milk, in particular the
decline in HM ARA and DHA with an increasing duration
of lactation, is less clear (2), and is considered to likely
reflect the depletion of maternal body stores of LCPUFA
rather than declining needs of the infant. With current
concepts, the total fat content and FA composition of formula
intended to be used by infants from birth up to 6 months
of age is fixed according to 1 specific recipe, and even
follow-on formulas for older infants often tend to have the
same lipid composition, even though arguments for more
differentiated staging of formula compositions have been
brought forward (38). Hence, formula-fed infants currently
lack the exposure to potentially functionally relevant changes
in lipid composition that breastfed infants experience.
Second, the HM lipid composition is associated with
various maternal factors, including lifestyle factors such
as smoking, body composition, dietary patterns, FADS
genotype, parity, and potentially child sex (9, 39–43). The
extent to which these maternal factors impact the HM lipid
composition varies among different FAs, and may also relate
to the observed geographical variation in the HM lipid
composition (5, 44). Previous investigations have provided
strong evidence that the maternal dietary intake of DHA
strongly affects the amount of this FA in HM (5–8, 45).
Likewise, the maternal LA intake is related to the LA content
of HM, although the predominant sources of LA in HM
postpartum are maternal body fat stores (∼70%) rather than
recent LA dietary intake (44, 46). This points to the relevance
of the maternal diet prior to and during pregnancy, which
modulates the LA content of maternal fat stores for the LA
content in HM. In contrast to LA, the level of ARA in HM
shows remarkably little variation in relation to differences in
the maternal ARA intake (5).
Third, in addition to variations in the HM lipid compo-
sition as a result of differences in individual dietary intakes
and other biological and lifestyle factors, marked temporal
changes in HM FA composition have been documented at a
population level, due to changes in habitual dietary intakes
and food composition. During the 20th century, dietary
intake of n–3 LCPUFAs declined, whereas the mean intake of
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LA markedly increased in Western/industrialized societies.
This has been driven by increased use of vegetable oils that
are rich in LA, such as soybean and sunflower oils, and the
increased consumption of processed and baked food items
that are rich in these oils, such as spreads, ready-to-use meals,
and pre-prepared sauces (47–49). These dietary changes were
reflected in markedly increased LA levels in the HM of
Western women between 1944 and 2000 (3, 50). Moreover,
considering more recent trends in the industrialized food
supply, such as the replacement of high–LA vegetable oils by
oils high in palmitic or oleic acids, such as palm oil, high-
oleic sunflower oil, rapeseed (classic canola) oil, and olive
oil, it may be postulated that the evolution of the HM FA
composition will continue, i.e., become higher in oleic acid
and lower in LA. A recent German study comparing HM FA
compositions in samples collected from 2 cohorts a decade
apart (2000 compared with 2012), however, suggests that the
increase in HM LA levels continues and that the increased
use of alternative oils is not (yet) visible at the HM level (51).
With regards to the selection of reference milk samples
to be used as a guide to infant formula FA compositions,
it is important to point out that no 2 HM samples are the
same; there are considerable differences between, as well as
within individuals. While pooling HM samples and data,
thereby taking into account the aforementioned factors, can
address this to some extent, it is impossible to account
for it completely, especially given that HM compositions
in part reflect patterns of edible fat consumption and the
populations studied across the globe. Moreover, it should
be considered that some of the variation in the FA content
and composition of HM may not necessarily translate into
favorable effects for the developing infant. Furthermore, in
addition to the FA content, differences in fat digestion and
digestibility between infants, including the lipase activity
and triglyceride structure affecting FA absorption, have to
be considered, as well as other effects related to differences
in the mode of feeding (formula feeding compared with
breastfeeding), which also have the potential to influence
the FA uptake and HM composition (52, 53). Hence, taking
the large inter- and intra-individual variations in HM FA
compositions into account, it is clear a single, ideal HM
composition does not exist as a guidance/reference to define
appropriate levels of FAs for a population-based adequate
intake.
Current Recommendations for Infant Formula
Lipid Composition
Recommendations set by the Codex Alimentarius (“Codex”)
of the FAO and WHO on formula composition state that
the fat content in infant formulas should be between 4.4 and
6.0 g/100 kcal [i.e., 40–55 Energy% (En%)], and include both
n–3 and n–6 essential FAs: at least 50 and 300 mg/100 kcal
ALA and LA, respectively (i.e., 0.45 and 2.7 En%). A guidance
upper level of 1400 mg/100 kcal (12.6 En%) is provided for
LA. While no maximum level was set for ALA, the LA/ALA
ratio in formula is set to be between 5 and 15. For preformed
DHA, Codex defines no minimum level and a guidance
upper level of 0.5% of total FAs (22 mg/100 kcal, 0.2 En%)
and specifies that the DHA content should be matched with at
least equal levels of ARA. The guidance upper levels stated are
based on an established history of apparent safe use, although
several populations with a high fish intake (e.g., Japanese
mothers) have far more DHA than ARA in HM (5). It is
acknowledged, however, that there is not enough information
for a science-based risk assessment to define strict maximum
allowable levels (54, 55).
The Codex recommendations (56) are partly based on
data on the FA compositions of HM from healthy, omniv-
orous women, as well as observations from infant feeding
studies (28, 55). The Codex represents guidelines on ade-
quate infant nutrition that are meant to provide guidance for
national and regional food standards. The Codex guidelines
are implemented in derived legislation in most countries to
ensure that infant formula is safe and meets the nutrient
and energy requirements of developing infants. In addition,
several national or regional authorities [e.g., the FDA in the
United States, the European Food Safety Authority (EFSA)
in the European Union, and Food Standards Australia New
Zealand (ANZ) in Australia and New Zealand] provide
guidance on infant formula compositions based on their own
expert consultations. An overview of the recommendations
by Codex and regulations set by various local authorities
are provided for LA, ALA, ARA, and DHA in Figure 1,
as well as the ranges of these FAs in HM. Figure 2 in the
Text Box illustrates the metabolic pathway for conversion
of ALA and LA to their respective longer chain metabolites
(57).
Global and national/regional standards are periodically
updated with the intention of improving guidelines. Changes
are based on emerging scientific insights on functional and
compositional properties of FAs in nutrition and/or infant FA
requirements. As an example of evidence-based adaptations
to guidelines or regulations, during the last decades it became
evident that an adequate nutritional supply of preformed
DHA to infants has direct health benefits (58). As a
result, the most recent European Commission (EC) directive
(2016/127) (59) now prescribes the mandatory addition
of preformed DHA to infant formula, as opposed to its
optional addition in the previous versions of these guidelines.
Conversely, and not in line with Codex recommendations,
specific regulations on the addition of preformed ARA to for-
mula (in conjunction with DHA) were deemed unnecessary,
as it was considered that there was no conclusive evidence
of functional effects of preformed ARA (59–61). This aspect
of the European regulation is controversial. Of particular
relevance to this paper is that having no ARA in formula
results in an FA composition of formula deviating further
from HM FA compositions, where both ARA and DHA are
always present (5). In response to the release of the DHA
recommendations, arguments were made by experts that the
ARA content of infant formulas should be at least equal to
that of DHA (55, 62). Following this reasoning, the addition
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FIGURE 1 Boxes represent the minimum and maximum recommended/stipulated levels of LA, ALA, ARA, and DHA as set by Codex and
various local regulatory bodies; values are expressed as mg/100 kcal and are calculated assuming 3.5 g fat/100 mL for infant formula. (A)
No maximum level defined; (B) no minimum level defined (addition is not mandatory); (C) LA/ALA ratio needs to be between 5 and 15; (D)
addition at maximum of 1% of total FA; (E) ARA/DHA ratio ≥1; (F) guidance upper level is 0.5% of total FA; and (G) shall not exceed n–6
LCPUFA. The box plot at right represents the median, upper, and lower quartiles and the range (minimum to maximum) in which these
FAs are present in HM; values are expressed as mg/100 kcal and are calculated assuming 3.3 g fat/100 mL and using mean values in milk of
mothers of term infants (average colostrum, transitional, and mature milk) that were reported in 50 studies (60 groups varying in size from
5 to 602 subjects) published between 1985 and 2018 that were included in a recent review on HM FA composition (2). Abbreviations: ALA,
α-linolenic acid; ANZ, Australia New Zealand; ARA, arachidonic acid; CN current, China standards as published in February 2021 and
mandatory from February 2023 onwards; CN previous, China standards before February 2021; EFSA current, European Food Safety
Authority standards mandatory from February 2020 onwards; EFSA previous, European Food Safety Authority standards before February
2020; HM, human milk; HM ref, human milk reference; LA, linoleic acid; LCPUFA, long-chain PUFA; RU, Russia.
of preformed ARA may allow for a decrease in the LA levels of
formula.
Evidence Base for the (Recently Adapted) LA
and ALA Recommendations
Although >200 different FA species have been identified in
HM, there is a tendency for some FAs to become the focus
of intense scrutiny, including by committees and panels. As a
result, other long-established constituents may not have been
studied despite their potential functional relevance; in some
cases, those constituents have never or have not recently been
investigated or subjected to randomized controlled trials
(RCTs). Constituents that have not received much attention
in recent years include LA and ALA.
The minimal levels of LA set in the current guidelines
are largely based on conclusions drawn from clinical experi-
ments in the 1940s and 1950s that evaluated the essentiality of
dietary LA intake in infants. Formulas very low in or devoid
of any fat resulted in skin pathology (dryness and scaling)
and in growth faltering in infants (28, 63–65). In preclinical
models, LA deficiency resulted in severe impairments in
renal function and fecundity in animals (64, 66, 67), all of
which could be alleviated by providing LA. Minimal required
levels of LA were found to be around 2 weight% (w%) of the
total fat intake (i.e., 120 mg/100 kcal). It must be stressed,
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FIGURE 2 Metabolic pathways and interconversions of PUFAs.
Adapted from Gibson et al. (57) with permission from Elsevier. Not
shown are the metabolic steps required for activation of FAs to
enter the pathways, and the steps required to accept synthetic
products from the pathway. Abbreviations: AdrA, adrenic acid; ALA,
α-linolenic acid; ARA, arachidonic acid; β-oxy, β-oxydation; DGLA,
di-homo-γ -linolenic acid; desat, desaturase; DPA3,
docosapentaenoic acid n–3; DPA6, docosapentaenoic acid n–6;
elong, elongase; GLA, γ -linolenic acid; LA, linoleic acid; SDA,
stearidonic acid.
however, that these studies were done in the absence of
ALA and a preformed LCPUFA supply. Interestingly, a recent
report demonstrated that LA requirements in the presence of
ALA are lower (1%–1.5%) than the historical 2% of energy
intake value in rats, suggesting there may be a need to also
reconsider the minimum LA recommendations for infants
(68).
The maximal recommended LA intake, however, was less
clear and rather arbitrarily set at a level seldom encountered
in HM at that time, and based on experimental indications
of possible untoward effects of high LA intakes and high
dietary LA/ALA ratios. In the 1980s, a UK working group
concluded that no obvious adverse effects were observed in
infants raised on a formula with close to 60 w% LA of total
fat (29), but the working group raised theoretical concerns
with regard to the vitamin E requirements of the infants (31).
Subcutaneous fat deposited in those infants was found to
comprise 25 w% LA by 6 wk, which increased up to 46 w% at
12 wk. Red blood cell membrane phospholipids were found
to contain increased LA levels in infants fed this formula
compared to their breastfed peers. Other changes in the FA
composition due to high LA dietary levels were hypothesized,
but no clear short- or long-term harm was identified as long
as the vitamin E supply was sufficient. The UK working group
set a safe maximal LA level of 20% of the FA in a formula with
6 g fat/100 kcal, which equates to 1200 mg LA/100 kcal. This
is the maximal level of LA set in the current European Union
guidelines.
The essentiality of ALA has been established in animal
studies only, leading to a recommended intake of 0.5% of
the total caloric intake for infants (67). A clear role for
ALA in infant development was never investigated, and
clinical data on minimal requirements of ALA in infants,
or on safe maximal intake levels, are lacking. Preclinical
rodent data, similar to those which established LA and ALA
as required in the absence of preformed LCPUFAs, show
conclusively that diets with ARA and DHA and without any
other source of n–6 or n–3 FAs are able to support normal
growth and development, including cognitive development
through 10 generations, and suggest improved fertility with
advancing age compared to conventional soybean oil–based
diets, which are high in LA and lacking ARA and DHA (4,
69). Based on these insights, LA and ALA may in fact not be
essential as long as a sufficient level of preformed LCPUFA
(DHA and ARA) is provided.
In the latest EC directive, the level of LA is set between
500 and 1200 mg/100 kcal (10%–25% of total FA) and the
level of ALA is set between 50 and 100 mg/100 kcal (1%–2%
of total FA) (59). Compared to the previous EC directive of
2006 (70), this stipulates a higher minimum addition of LA
and a lower maximum of ALA (see Figure 1). The decision
to lower the maximal allowed ALA levels might have been
considered because of the now-mandatory addition of DHA.
It was reasoned that adequate amounts of preformed DHA
should be provided in the diet to meet infant requirements,
allowing a lower level for its precursor ALA. The basis of this
seems to be that whereas ALA can function as a precursor
for DHA (see Text box), the endogenous conversion of
ALA to DHA is regarded as insufficient during infancy to
meet DHA requirements, and is also known to depend on
the infant’s genotype with respect to the desaturase and/or
elongase enzymes required for ALA to DHA conversion (9,
42, 43). The higher levels of LA in the new guidelines (a
higher absolute minimum, as well as a higher LA/ALA ratio
due to the lowered maximum addition of ALA) are thought
to facilitate LA conversion to ARA, given that the addition
of preformed ARA is not proposed (71). While this logic
may seem sound (see Text box), whether adequate ARA
levels can be achieved from LA conversion to meet the high
metabolic demands of growing infants has been questioned
(72). Interestingly, although a higher LA supply might
theoretically favor endogenous ARA synthesis (see Text box),
there is evidence coming from studies in adults that this
relationship is absent or much more complex (73). As an
example, targeted dietary manipulations in adults showed
that a 66% reduced LA intake (from 7.4 to 2.4 En%), along
with a 50% reduced preformed ARA intake, only resulted
in a 5% reduction (borderline significant) in circulating
ARA levels (74). This indicates that circulating plasma ARA
levels neither show a linear association with nor are a mere
reflection of the dietary LA or ARA intake, but appear
to depend on endogenous production (capacity) aimed at
maintaining physiologically adequate levels. Moreover, it
should be noted that high dietary LA levels may suppress
endogenous synthesis and tissue accretion of all n–3 FAs (see
Text box), thus in effect creating a metabolic requirement
for preformed DHA (75, 76). Conversely, a lower dietary LA
supply would theoretically allow for lower levels of the DHA
supply (74, 77).
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Text Box
Human milk and infant formula include the essential
fatty acids (EFAs) LA (18:2 n–6) and ALA (18:3 n–3).
After ingestion, these 18-C EFAs can be converted to
LCPUFAs (≥20-C), including n–6 ARA and n–3 DHA,
by desaturase and elongase enzymes (see Figure 2); this
process takes place primarily in the liver, although in
infants the capacity to synthesize LCPUFAs from EFAs
is low (8, 71). HM also contains preformed LCPUFAs
(both n–6 and n–3), and so may infant formula.
The n–6 and n–3 PUFAs use the same set of enzymes,
and therefore compete for conversion. Consequently,
the absolute amounts of both PUFA type, as well as their
ratio, affect the balance between n–6 and n–3 LCPUFA
synthesis. A high supply of LA can limit n–3 LCPUFA
synthesis and lead to excessive n–6 LCPUFA synthesis.
The conversion of EFAs, as well as of the intermediates
n–6 AdrA and n–3 DPA3 to n–6 DPA and DHA,
respectively, involves the FADS2-coded enzyme 6-
desaturase via either the Sprecher pathway or FADS2-
coded 4-desaturase (78, 79). A high supply of LA can
therefore also limit the conversion rates of n–6 and n–3
FA intermediates.
LA and ALA, as well as their metabolites, are
important constituents of biological membranes and
immune-modulating compounds, as they are precursors
in the biosynthesis of eicosanoids, signaling lipidic
molecules with an important function in the immune
system (allergy and inflammation) and in adipose
tissue development (80). The n–6 and n–3 PUFAs
compete for uptake from the plasma to organs, such
as the developing brain, where ARA and DHA cannot
be synthesized locally in sufficient amounts (81). A
disproportionally high supply of LA over ALA will be
reflected in a disbalance in the types of end products,
including LCPUFAs, eicosanoids, and PGs, synthesized
from the precursors supplied and in their availability
for incorporation in and/or use by organs and tissues.
Although circulating PUFA levels do not necessarily
reflect local tissue levels, a high circulating n–6 PUFA
status may inhibit the local uptake and incorporation
of (preformed) n–3 LCPUFAs in membranes (77, 82,
83). The dietary supply with n–3 LCPUFAs for health
benefits may therefore not be effective when combined
with an imbalanced intake of LA/ALA (71).
Potential Effects of a High Dietary LA Intake in
Early Life
Many organs and systems undergo important developmental
steps, particularly during the first 1000 d from conception
to a child’s second birthday. The dietary FA composition in
the early postnatal period was proposed to modulate growth
and development, and ultimately to affect health in later life
(84). Moreover, it was postulated that an increased dietary LA
intake and a decrease in the ALA supply early in life might
have negative effects on short- and long-term health. The
changes in human dietary habits over recent decades in West-
ern society, including higher intakes of LA, have coincided
with higher incidences of obesity, immune-related diseases,
and neuropsychiatric diseases at a population level (3, 84–
89). Although it is important to note that an association does
not imply any causal relationship, this has nevertheless led
to speculation that exposure to higher LA intakes before
birth and in early infancy might be associated with altered
development and long-term consequences for health and
disease risks. The increased dietary LA supply over the last
decades in Western populations is reflected in an increasing
mean HM LA content (3). Some observational studies
propose that high LA in HM might be associated with poor
neurocognitive outcomes (90–93), excessive weight gain and
a higher obesity risk (50, 94), and an increased risk for atopic
eczema and allergic responses (95–97), although there is
no direct clinical evidence supporting a causal relationship.
LA and ALA are precursors for n–6 and n–3 LCPUFAs,
respectively, as well as a wide range of other metabolites
and bioactive compounds (see Text box). Dietary intakes of
LA and ALA, and the balance between them, therefore have
the potential to affect the LCPUFA status, and thus impact
immune and neural functions, as well as the development
of adipose tissue, particularly if preformed LCPUFAs are not
adequately provided. The following paragraphs elaborate on
the evidence base for this hypothesis.
LCPUFA status
Circulating n–3 LCPUFA plasma levels in infants are strongly
affected by the dietary supply of preformed n–3 LCPUFAs
(6, 45). However, intervention studies in humans where the
dietary n–6/n–3 ratio is modified by adapting only the levels
of the precursors LA and ALA are scarce. The evidence from
available trials in adults suggests that the n–3 LCPUFA status
may be increased by specifically reducing dietary LA intakes
to very low levels (74, 76, 98–101). Udell and colleagues
(102) reviewed the outcomes of clinical intervention studies
in infants using formula with an increased ALA level,
thereby also resulting in lower dietary LA to ALA ratios,
and concluded that an increasing ALA supply improved the
infant DHA status, in contrast to many studies in adults (8).
In line with these findings, the infant DHA status was also
increased when the dietary ALA supply was increased while
LA was lowered (103, 104). Importantly, these studies in
infants were performed using formulas devoid of preformed
LCPUFAs, and the ALA levels were substantially above the
current recommended range for ALA. With the mandatory
presence of preformed DHA in current infant formulas, the
contribution of ALA as precursor to DHA is likely to be
limited, since preformed DHA consistently raises plasma
DHA levels (8, 71, 78, 105).
Immune function and allergy
The immune system develops early in life. LA and ARA have
been proposed to induce pro-inflammatory effects because
of the range of pro-inflammatory eicosanoid mediators (e.g.,
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PGs, leukotrienes, see Text box) derived from LA and ARA
by cyclo- and lip-oxygenases (80, 106, 107). The levels of
these PUFAs, and therefore their downstream products, are
postulated to play a role in processes such as inflammation
and thrombosis and, as suggested in more recent studies, in-
fluence the response to viruses, including severe acute respi-
ratory syndrome coronavirus 2, that are known to be related
to such signaling molecules (78). However, lipoxins derived
from ARA may also induce resolution of inflammation. A
high dietary supply of LA was proposed to facilitate devel-
opment of allergic sensitization, and it was speculated that
enhanced production of the ARA-derived eicosanoid PGE2
might induce multiple T helper 2 cell–associated diseases,
most notably atopic dermatitis and asthma (108–110). PGE2
might also promote the production of IgE, an immunoglob-
ulin associated with allergic responses (110). Furthermore,
LA might affect signal transduction pathways involved in im-
mune functions by binding to transmembrane and/or intra-
cellular receptors or altering other signaling molecules (48).
While higher intakes of LA-rich vegetable oils, such as con-
ventional soybean oil, have been associated with an increased
incidence of allergic disease in children (111), confounding
of the association with other variables associated with allergy
risks must be considered. In preclinical models, excessive di-
etary LA intake promotes vascular inflammation (112) and is
associated with allergic responses (113, 114), but it is not clear
whether these findings can be extrapolated to human infants.
Neurocognitive function
Early in life, structural and functional development of the
brain is enabled by high levels of DHA and other substrates
sourced from the blood stream and accumulating in neuronal
tissues. In the absence of an adequate preformed DHA supply,
a high dietary LA supply might reduce the brain DHA uptake,
since 1) the capacity for endogenous n–3 LCPUFA synthesis
will most likely be reduced by high LA levels competing with
ALA for conversion; and 2) higher n–6 LCPUFAs in the
circulation compete with n–3 LCPUFAs for incorporation
into neuronal membranes, resulting in relatively lower levels
of DHA and other n–3 LCPUFAs in the brain [see for review
(115)]. Although brain FA profiles cannot be studied in
clinical trials, autopsy studies in infants that suffered from
sudden (cot) death revealed differences depending on diet.
Lower brain DHA and higher n–6 docosapentaenoic acid
(DPA) contents were observed in infants fed formulas with a
relatively high LA content and no preformed DHA compared
to both breastfed infants and formula-fed infants exposed to
a high LA/ALA ratio (116–119). Evidence from preclinical
studies shows that postnatal dietary LA levels are inversely re-
lated to the DHA content in the developing brain. In contrast,
the level of, in particular, n–6 DPA, which has no neurode-
velopmental relevance and typically accumulates if there is an
n–3 PUFA deficiency (120, 121), is also increased following
a high LA supply (82, 83, 122, 123). Supplementation with
DHA and ARA did not prevent some of these typical changes
in the brain FA profile caused by the high LA supply (122).
In contrast, specifically lowering the LA supply early in life
was shown to positively affect structural development of the
brain and to improve neurocognitive function later in life in
experimental animal models (124, 125).
Adipose tissue development and metabolic syndrome
White adipose tissue (WAT) development occurs early
in life and comprises proliferation and differentiation of
preadipocytes to mature adipose cells. In humans, the WAT
storage capacity—the number of adipocytes that can be
filled throughout life—is established during childhood and
adolescence (126). The n–3 and n–6 FAs may differentially
modulate proliferation and differentiation of preadipocytes,
with LA and ARA and their eicosanoid metabolites stimu-
lating adipogenesis via several mechanisms, including gene
transcription, mRNA processing, and posttranscriptional
processes (3, 127, 128). Data from preclinical studies suggest
that exposure to a high LA supply early in life predisposes
an infant to later life metabolic diseases, including obesity
and hepatic steatosis (3, 127, 129–131), whereas low LA
intake, as well as dietary n–3 LCPUFA supplementation, may
program an infant toward reduced fat mass accumulation
(132, 133). It is important to note, however, that this has not
been a consistent finding across all preclinical studies, and
the interpretations of these data are often complicated by the
fact that exposure to the low-LA or high-DHA diet is not
confined only to the preweaning period (134). While positive
associations between cord blood n–6 PUFAs and fat mass in
childhood have been reported in human studies, no causal
relationships have been established (135). Although there
is some indication that HM DHA levels may be associated
with beneficial effects on childhood BMI (136), the potential
for reducing fat deposition (in adipose tissue) in human
infants through n–3 FA supplementation during pregnancy
and/or breastfeeding is not supported by the current body of
evidence (137–139).
Gaps in Knowledge
The latest EC directive on infant and follow-on formula
compositions stipulated higher minimal LA and lower maxi-
mal ALA contents, with a possible increase of the LA/ALA
ratio, in the presence of DHA and potentially also ARA.
Based on experimental and observational data described
in the previous sections, potential adverse effects of these
changes are conceivable and should be carefully explored and
considered. However, the complexity of clinical intervention
trials in general has posed a challenge for generating
sufficient evidence for the specific contributions and optimal
levels of distinct FAs in infant nutrition, such as LA, ARA,
and ALA. For example, measurable clinical endpoints may
stretch well beyond the end of any intervention study.
Although several clinical trials have investigated the effects
of a high compared with low n–6/n–3 ratio early in life on
infant development and health outcomes, most studies focus
on supplies of preformed n–3 and n–6 LCPUFAs. To the
best of our knowledge, there are no clinical trials to date in
which the effects of LA and ALA levels in infant formula
are studied in the presence of preformed LCPUFAs. This is
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critical given that the available preclinical evidence indicates
that the relationship between n–6 and n–3 FA intakes and
circulating DHA levels is more complex than the simple
concept of a ratio and also depends on the total dietary PUFA
provided.
Rationale and Hypothesis Behind Health
Benefits of Lowering LA Levels in Formula
Based on our current understanding of lipid biochemistry
and functionality and on mainly preclinical evidence, it can
be postulated that a disproportionally high LA intake in
infants may reduce n–3 LCPUFA synthesis and/or accretion,
resulting in a lower DHA status (in the absence of preformed
DHA). Conversely, the synthesis of n–6 LCPUFA–derived
pro-inflammatory eicosanoids and adipogenic cytokines
might be increased, with a potential impact on the de-
velopment and functioning of the immune system, brain,
adipose tissue, and other organs. It can be hypothesized that
lowering the LA content in infant formula, without changing
ALA, DHA, and ARA levels, might support an enhanced
infant n–3 LCPUFA status and thereby support healthier
infant development. Potentially, this might lead to further
reconsideration of the level of preformed DHA needing to
be added to formula. This hypothesis may have considerable
relevance for long-term health outcomes, and hence should
be thoroughly explored.
Developing a Better Evidence Base for
Adequate and/or Optimal LA Intakes in Infants
To create clarity on optimal and safe LA levels in infant
formula intended for healthy, term infants, as well as to
generate convincing evidence for potential health benefits,
including the possible reduction of disease risks later in life,
more clinical evidence is needed. For example, as a first step,
a focused proof-of-principle study could be performed to
show the impact of an infant formula with low compared with
high (current) LA levels on the LCPUFA status in healthy,
term infants. Such a study could be done as a relatively small
RCT, using potentially an infant formula with a maximal LA
content of 300 mg/100 kcal (i.e., the minimum level defined
in the previous EFSA recommendations and current Codex)
and a formula containing at least 500 mg/100 kcal LA (in line
with current EFSA recommendations). In order to provide
valid data, both the experimental (low LA) and control (high
LA) formulas should contain similar ALA levels, as well as
preformed DHA and ARA, the latter preferably in equal
amounts (i.e., around 25 mg/100 kcal), following recently de-
scribed recommendations (55). In addition, the experimental
or control formula should be the sole source of nutrition up
to at least 4 months of age. The study may include a breastfed
reference group, as well as a group fed a formula low in
LA but without ARA, to evaluate the impact of the absence
of preformed n–6 LCPUFAs, as allowed by current EFSA
recommendations. Crucial in such a study will be the defi-
nition of the LCPUFA status and the determination of how
to assess this optimally. Plasma and erythrocyte FA levels,
measuring both precursor FAs and LCPUFAs (140), could
be used to monitor the FA status over time. Such a proof-
of-principle study should be conducted in a well-defined
and fairly homogenous population to reduce the impact
of potential sources of variation, as mentioned above (e.g.,
genotype, phenotype, and maternal environmental factors).
It is important to note that this has the inherent yet acceptable
limitation that the outcomes cannot be directly extrapolated
to other (sub-)populations, including preterm infants.
The proposed adaptations of the infant formula recipes to
be tested in the trial may raise additional challenges that will
impact the overall FA composition of infant formula, since
lowering the LA content requires an increase in another FA
to keep the total contribution of fat equal. Using HM as guid-
ance in how to do this, a higher contribution of oleic acid or
a saturated FA might be the most logical solution. Although
also increasing the ALA content may be considered due to
ALA’s role as precursor for n–3 LCPUFA, preclinical evidence
in rats shows that endogenous DHA synthesis may be para-
doxically reduced when the ALA supply is too high (141).
Based on the established clinical evidence that associates
the infant blood FA status with functional outcomes,
emphasizing brain developmental milestones and immune
function, it may be assumed that within reasonable ranges a
higher n–3 LCPUFA status could be beneficial to the devel-
oping infant (142). This should be confirmed in follow-up
clinical studies that will also consider functional outcomes,
such as growth; body composition; the incidence of atopic
disease; neurodevelopment, including vision development;
and cognition in the long term. Whereas the effects of
dietary LCPUFA intake after weaning will contribute to the
outcomes, concrete clinical endpoints would preferably be
assessed until an age of 2 y (∼1000 d) and with follow-up
beyond (at 5 or even 10 years of age). Such data could provide
the required new evidence that is needed to reconsider
current guidelines for the level of LA in formula for healthy,
term infants and may help define levels that will support
healthier development of infants across the population.
Conclusion
The balance of dietary LA and ALA levels and preformed n–
6 and n–3 LCPUFAs in early life nutrition has the potential
to affect the LCPUFA status and impact immune, neural,
and adipose tissue development. The latest EC directive
on infant formula compositions stipulated increasing the
minimal LA content and lowering the maximal ALA content
in infant formula, thereby increasing the LA/ALA ratio, in
the presence of DHA and optionally also ARA. Based on
the current understanding of lipid biochemistry and on the
available scientific, mainly preclinical, evidence, it may be
postulated that a relatively high LA intake in infants could
reduce n–3 LCPUFA synthesis and/or accretion, resulting in
a lower DHA status. However, the available preclinical evi-
dence indicates that the relationship between n–6 and n–3 FA
intakes on circulating DHA levels is more complex, and is not
only the direct result of the LA/ALA ratio but also depends on
the total (preformed) dietary PUFAs provided. We conclude
that a clear gap in knowledge exists regarding the potential
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impacts of LA and ALA levels in infant formula in the pres-
ence of preformed LCPUFAs, as in current formulas. Hence,
an urgent need exists for well-designed clinical intervention
trials to create clarity about optimal and safe levels of LA and
its long-term implications on functional health outcomes.
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